Vontobel Holding Ltd. Acquires Shares of 10,647 Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)

Vontobel Holding Ltd. purchased a new stake in shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 10,647 shares of the company’s stock, valued at approximately $62,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of OLMA. Point72 Asset Management L.P. grew its position in Olema Pharmaceuticals by 14.8% during the third quarter. Point72 Asset Management L.P. now owns 3,687,374 shares of the company’s stock valued at $44,027,000 after acquiring an additional 475,447 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its stake in shares of Olema Pharmaceuticals by 168.5% during the third quarter. Charles Schwab Investment Management Inc. now owns 330,761 shares of the company’s stock valued at $3,949,000 after purchasing an additional 207,565 shares during the period. Great Point Partners LLC lifted its stake in Olema Pharmaceuticals by 25.5% in the third quarter. Great Point Partners LLC now owns 1,000,000 shares of the company’s stock worth $11,940,000 after acquiring an additional 203,120 shares during the period. JPMorgan Chase & Co. lifted its stake in Olema Pharmaceuticals by 658.7% in the third quarter. JPMorgan Chase & Co. now owns 181,032 shares of the company’s stock worth $2,162,000 after acquiring an additional 157,171 shares during the period. Finally, Wellington Management Group LLP lifted its stake in Olema Pharmaceuticals by 10.8% in the third quarter. Wellington Management Group LLP now owns 1,002,685 shares of the company’s stock worth $11,972,000 after acquiring an additional 97,428 shares during the period. 91.78% of the stock is currently owned by institutional investors.

Olema Pharmaceuticals Price Performance

Shares of NASDAQ:OLMA opened at $4.99 on Friday. Olema Pharmaceuticals, Inc. has a 1-year low of $4.60 and a 1-year high of $16.62. The business has a fifty day moving average price of $5.69 and a 200-day moving average price of $9.40. The company has a market capitalization of $285.93 million, a PE ratio of -2.28 and a beta of 2.05.

Insider Buying and Selling

In other Olema Pharmaceuticals news, Director G. Walmsley Graham sold 700,761 shares of the firm’s stock in a transaction dated Tuesday, December 17th. The stock was sold at an average price of $6.75, for a total value of $4,730,136.75. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, major shareholder Bain Capital Life Sciences Inv acquired 300,000 shares of the stock in a transaction dated Wednesday, January 8th. The shares were bought at an average cost of $5.76 per share, for a total transaction of $1,728,000.00. Following the completion of the transaction, the insider now owns 7,800,000 shares in the company, valued at approximately $44,928,000. This represents a 4.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last ninety days, insiders sold 773,797 shares of company stock worth $5,414,609. 19.40% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a “buy” rating and issued a $30.00 price objective on shares of Olema Pharmaceuticals in a report on Wednesday, December 11th.

Olema Pharmaceuticals Company Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.